Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VCYT vs MYGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VCYT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

VCYT Overall Winner 6-Pillar Tally: VCYT 5 – 1 MYGN Matrix Metrics: VCYT 8 – 2 MYGN

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Myriad Genetics Inc (MYGN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas MYGN carries 46.2/100 (HOLD) at $5.57 (54.0x Forward P/E, -13.3% operating margin).

  • Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile MYGN trades in a Markup technical trend (SURGE options phase, RSI 52.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VCYT vs MYGN
VCYT NASDAQ Head-to-Head Winner
Veracyte, Inc.
Services-Medical Laboratories
$24.01
-1.32% 1D
Market Cap $2.0B
TTM Revenue $582M
Forward P/E 15.3x
Beta / 30D Vol 3.01β · 199% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.8%), weak momentum, RSI 28
RSI-14: 27.8 · SMA20: $39.20 · SMA50: $41.79
MYGN NASDAQ
Myriad Genetics Inc
In Vitro & In Vivo Diagnostic Substances
$5.57
-1.59% 1D
Market Cap $542.9M
TTM Revenue $804M
Forward P/E 54.0x
Beta / 30D Vol 0.68β · 122% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 30.0 Fund 43.0 Flow 56.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (30.2% over 20 days), RSI 52
RSI-14: 52.1 · SMA20: $5.94 · SMA50: $4.80

6-Pillar Scorecard Institutional Category Breakdown (VCYT 5 – 1 MYGN)

Columns: Metric · VCYT · MYGN
1. Valuation Multiples VCYT
Forward P/E 15.3x 54.0x
Trailing P/E 15.8x 54.0x
PEG Ratio N/M 1.40x
EV / Revenue 3.1x 0.8x
2. Growth & Scale VCYT
Revenue Growth (YoY) +15.1% -1.5%
Earnings Growth (YoY) +58.3% +0.0%
TTM Revenue (USD) $582M $804M
Market Cap $2.0B $542.9M
3. Profitability & Quality VCYT
Gross Margin 74.2% 68.3%
Operating Margin 15.0% -13.3%
Net Profit Margin 21.8% -16.1%
Return on Equity (ROE) 9.4% -40.2%
4. Balance Sheet & Cash Flow VCYT
Cash Generation (TTM) $162M -$38M
Cash Flow Margin 27.8% -4.7%
Net Cash / Leverage $159M Net Cash $102M Net Debt (0.78x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VCYT
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 197.3% (47th %ile) 124.6% (22nd %ile)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat MYGN
OpEx & R&D Intensity 59.2% of Rev ($344M) 81.6% of Rev ($656M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VCYT (8) vs MYGN (2)
Institutional Metric VCYT MYGN Criterion Row Edge
Market Capitalization
Scale
$2.0B $542.9M Larger Scale VCYT
Trailing P/E Ratio
Valuation
15.8x 54.0x Lower Multiple VCYT
Forward P/E Ratio
Valuation
15.3x 54.0x Lower Multiple VCYT
Revenue Growth (YoY)
Growth
+15.1% -1.5% Higher Growth VCYT
Operating Margin (TTM)
Profitability
15.0% -13.3% Higher Margin VCYT
Net Profit Margin
Profitability
21.8% -16.1% Higher Margin VCYT
Return on Equity (ROE)
Capital Efficiency
9.4% -40.2% Higher ROE VCYT
52-Week Range Position
Momentum
5% ($22–$61) 53% ($3–$8) Stronger Trend MYGN
Beta / 30D Volatility
Risk Regime
3.01β · 199% Vol 0.68β · 122% Vol Lower Realized Risk MYGN
Unified Institutional Score
Composite Signal
49.1 / 100 (HOLD) 46.2 / 100 (HOLD) Higher Composite VCYT
Trailing 12M Revenue (USD)
Operating Scale
$582M $804M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.2% 68.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev 1.40x PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$162M ($159M Net Cash) -$38M ($102M Net Debt (0.78x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MYGN +84.27 pp
VCYT: -44.32% · MYGN: +39.95%
3M Horizon MYGN +135.06 pp
VCYT: -40.98% · MYGN: +94.08%
6M Horizon MYGN +94.74 pp
VCYT: -42.14% · MYGN: +52.6%
1Y Horizon MYGN +27.5 pp
VCYT: -39.78% · MYGN: -12.28%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VCYT Revenue MYGN Revenue VCYT Op. Margin MYGN Op. Margin Margin Leader
FY2018 $90M $740M -24.2% 16.4% MYGN
FY2019 $120M $850M -12.6% 0.9% MYGN
FY2020 $120M $560M -30.1% -52.0% VCYT
FY2021 $220M $690M -37.3% -27.6% MYGN
FY2022 $300M $680M -13.9% -20.7% VCYT
FY2023 $360M $750M -23.8% -34.2% VCYT
FY2024 $450M $840M 3.6% -14.7% VCYT
FY2025 $520M $820M 11.2% -47.0% VCYT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VCYT BREAKDOWN
99d in phase · OBV DISTRIBUTION
Current IV 197.3%
IV Percentile 47th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MYGN SURGE
12d in phase · OBV DISTRIBUTION
Current IV 124.6%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact MYGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VCYT Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.0B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 59.2% of Rev ($344M)
90D Engineering Disclosures 0 Published
MYGN Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $542.9M market capitalization and -13.3% operating margin.
OpEx & R&D Reinvestment 81.6% of Rev ($656M)
90D Engineering Disclosures 0 Published

Investor FAQ VCYT vs MYGN Key Questions & Quantitative Answers

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Myriad Genetics Inc (MYGN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas MYGN carries 46.2/100 (HOLD) at $5.57 (54.0x Forward P/E, -13.3% operating margin). Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile MYGN trades in a Markup technical trend (SURGE options phase, RSI 52.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VCYT leads the Growth & Scale pillar: VCYT posts +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin), compared with MYGN at -1.5% YoY revenue growth and +0.0% YoY earnings growth on $804M TTM revenue (68.3% gross margin, -13.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VCYT cumulative revenue shifted +477.8% while MYGN shifted +10.8%. In operating R&D and SG&A reinvestment, VCYT deploys 59.2% of Rev ($344M) (0 90-day corporate R&D disclosures) versus 81.6% of Rev ($656M) (0 disclosures) for MYGN.

VCYT screens cheaper on headline valuation multiples. VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin), whereas MYGN trades at 54.0x Forward P/E, 54.0x Trailing P/E, 1.40x PEG, and 0.8x EV/Revenue (-4.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VCYT (9.4% ROE) versus MYGN (-40.2% ROE) capital efficiency.

In options market volatility and institutional positioning, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk). By comparison, MYGN carries 124.6% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.68β · 122% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.